Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SYL 1801

Next Previous
Drug Profile

SYL 1801

Alternative Names: SYL-1801

Latest Information Update: 15 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sylentis
  • Class Eye disorder therapies; Gene therapies; Small interfering RNA
  • Mechanism of Action NRARP protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Age-related macular degeneration
  • No development reported Choroidal neovascularisation

Most Recent Events

  • 05 May 2025 Efficacy and adverse events data from phase II trial in Age-related macular degeneration released by Sylentis (Ophthalmic)
  • 19 Dec 2024 Sylentis completes a phase-II trial in Age-related macular degeneration in Czech Republic, Slovakia, Hungary and Poland (Ophthalmic) (EudraCT2022-000214-34) (NCT05637255)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Choroidal-neovascularisation(In volunteers) in Spain (Ophthalmic)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top